Arlington Partners’s PTC Therapeutics PTCT Stock Holding History

Arlington Partners’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-3	Closed	–	–	403
2020 Q4	$0	Buy	+3	New	+$177	﹤0.01%	234

Other funds holding PTCT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Arlington Partners's PTCT Position: Q1 2021 in Review

Arlington Partners sold out of PTC Therapeutics (PTCT) in Q1 2021, closing a stake of 3 shares.

Arlington Partners first reported a position in PTCT in Q4 2020 and held it in 1 quarter. The position peaked at $0 in Q4 2020. 208 funds tracked by Wall St. Rank hold PTCT as of Q1 2021.

Arlington Partners reported no remaining PTC Therapeutics position as of Q1 2021 after selling out during the quarter.
Arlington Partners sold 3 PTC Therapeutics shares in Q1 2021.
Arlington Partners first reported a position in PTC Therapeutics in Q4 2020 and held it in 1 quarter.
Arlington Partners's PTC Therapeutics position peaked at $0 in Q4 2020.
208 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2021.

Based on Arlington Partners's 13F filing for Q1 2021, filed 19 Apr 2021.